Ondexxya (andexanet alfa): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Ondexxya
|
| Active substance |
andexanet alfa
|
| Therapeutic area (MeSH) |
Drug-Related Side Effects and Adverse Reactions
|
| Regulatory outcome |
Variation
|
| DHPC type |
Safety signal
|
| Human ATC code |
V03AB
|
| Dissemination date |
17/06/2020
|